We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Cardiovascular Effects of Incremental Diesel Exhaust Inhalation in Middle-Aged Healthy GSTM1 Null Human Volunteers

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: March 8, 2012
Last Update Posted: March 8, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Haiyan Tong, Environmental Protection Agency (EPA)

Purpose: A growing body of epidemiological data suggests an increased risk of cardiovascular events associated with air pollutants. Reactive oxygen species (ROS) have been implicated as a potential mechanism for the adverse effects of air pollutants and genetic polymorphisms of the glutathione-s-transferases (GSTs) have been shown to participate in the antioxidant defenses to air pollutants. This study examined the dose effects of diesel exhaust exposure on the cardiovascular system in healthy middle-aged subjects.

Participants: Six healthy 50-75 year-old male and female subjects with GSTM1 null genotype had 3 sequential exposures to the diesel exhausts at concentrations approximately 100 µg/m3, 200 µg/m3, and 300 µg/m3 for 2 hours with a about 2 weeks of interval between exposures.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Further study details as provided by Haiyan Tong, Environmental Protection Agency (EPA):

Enrollment: 6
Study Start Date: July 2007
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Healthy middle-aged human volunteers


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy 50-75 year-old male and female subjects with GSTM1 null genotype.

Inclusion Criteria:

  • Age 50-75 years old generally healthy male and female.
  • Normal resting ECG.
  • Oxygen saturation greater than 94% at the time of physical exam.

Exclusion Criteria:

  • A history of angina, cardiac arrhythmias, and ischemic myocardial infarction or coronary bypass surgery.
  • Cardiac pacemaker.
  • Uncontrolled hypertension (> 150 systolic, > 90 diastolic).
  • Neurodegenerative diseases such as Parkinson's and Alzheimer disease.
  • A history of chronic illnesses such as diabetes, cancer, rheumatologic diseases, immunodeficiency state, known cardiovascular disease, chronic respiratory diseases such as chronic obstructive pulmonary disease or severe asthma.
  • History of bleeding diathesis.
  • Currently taking HMG-CoA reductase inhibitors for hyperlipidemia including lovastatin, pravastatin, simvastatin, and atorvastatin.
  • Currently taking beta-blockers to control hypertension and/or arrhythmias.
  • Use of oral anticoagulants.
  • Participants must refrain from all over-the-counter NSAIDs for a period of two weeks prior to exposure. Low-dose aspirin will be acceptable. Medications not specifically mentioned here may be reviewed by the investigators prior to a participant's inclusion in the study.
  • Subjects who are currently smoking or have smoking history within 1 year of study (defined as more than one pack of cigarettes in the past year).
  • Subject is pregnant, attempting to become pregnant or breastfeeding.
  • No exposure will be conducted within 4 weeks of a respiratory tract infection.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01548625

United States, North Carolina
EPA Human Studies Facility
Chapel Hill, North Carolina, United States, 27599
Sponsors and Collaborators
Environmental Protection Agency (EPA)
  More Information

Responsible Party: Haiyan Tong, Principal Investigator, Environmental Protection Agency (EPA)
ClinicalTrials.gov Identifier: NCT01548625     History of Changes
Other Study ID Numbers: DE pilot
First Submitted: March 5, 2012
First Posted: March 8, 2012
Last Update Posted: March 8, 2012
Last Verified: March 2012

Keywords provided by Haiyan Tong, Environmental Protection Agency (EPA):
risk of cardiovascular events